圣诺生物GLP-1原料药爆发? 上半年净利激增超三倍

Core Viewpoint - The strong performance of Shengnuo Biopharmaceuticals is driven by increased sales of GLP-1 raw materials, specifically Semaglutide and Tirzepatide, with significant growth in both revenue and net profit in the first half of 2025 [1][2] Financial Performance - Shengnuo Biopharmaceuticals reported a revenue of 338 million yuan, a year-on-year increase of 69.69% [1] - The net profit reached 88.96 million yuan, showing a substantial year-on-year growth of 308.29% [1] - The net profit after deducting non-recurring items was 89.48 million yuan, with a remarkable increase of 367.92% year-on-year [1] - The net cash flow from operating activities increased by 213.22% due to factors such as increased receipt of payments [1] Market Dynamics - GLP-1 drugs are recognized as "miracle drugs" for weight loss, with expanding indications in diabetes treatment, obesity management, chronic kidney disease (CKD), non-alcoholic fatty liver disease (NASH), and Alzheimer's disease [1] - The patent for Semaglutide will expire in 2026, attracting many companies to develop generic or modified new drugs, which is expected to increase the demand for raw materials [2] - Market institutions predict that global demand for GLP-1 raw materials may reach 50 tons by 2030, indicating a potential supply-demand imbalance [2] International Expansion - Shengnuo Biopharmaceuticals is actively expanding its overseas market, achieving significant breakthroughs in international sales, with overseas revenue reaching 187 million yuan, a year-on-year increase of over 240% [2] - The company is optimizing its product layout and accelerating the international registration and application process for raw materials [2] Research and Development - The company has improved its R&D output efficiency, obtaining certifications for Semaglutide raw materials from the Korean Food and Drug Safety Ministry, which supports market expansion [3] - Several core raw materials in the beauty peptide field have received international HALAL certification, aiding in global market expansion [3] - The company has successfully launched key projects to enhance production capacity, ensuring timely responses to new order demands [3] Strategic Focus - Shengnuo Biopharmaceuticals plans to continue focusing on the peptide pharmaceutical industry, accelerating R&D innovation and internationalization efforts [4] - The company aims to capture the market for peptide drugs in diabetes and obesity, while also strengthening its R&D and production advantages in major disease areas such as reproductive health, chronic hepatitis B, oncology, digestive, and immune systems [4]